By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
Currency | US Dollars |
Share Price | $ 132.22 |
Change Today | $ -0.43 |
% Change | -0.32 % |
52 Week High | $204.95 |
52 Week Low | $118.84 |
Volume | 1,083,013 |
Shares Issued | 145.80m |
Market Cap | $19,278m |
RiskGrade | 259 |
Strong Buy | 7 |
Buy | 6 |
Neutral | 20 |
Sell | 1 |
Strong Sell | 0 |
Total | 34 |
Time | Volume / Share Price |
16:00 | 233,911 @ $132.22 |
15:59 | 100 @ $132.15 |
15:59 | 100 @ $132.15 |
15:59 | 100 @ $132.23 |
15:59 | 100 @ $132.22 |
You are here: research